Hits of a high-throughput screen identify the hydrophobic pocket of autotaxin/lysophospholipase D as an inhibitory surface

Molecular Pharmacology

Volumn 84, Issue 3, 2013, Pages 415-424

  Fells, James I ^a   Lee, Sue Chin ^a   Fujiwara, Yuko ^a   Norman, Derek D ^a   Lim, Keng Gat ^a   Tsukahara, Ryoko ^a   Liu, Jianxiong ^a   Patil, Renukadevi ^a   Miller, Duane D ^a   Kirby, R Jason ^b   Nelson, Sandra ^b   Seibel, William ^b   Papoian, Ruben ^b   Parrill, Abby L ^c   Baker, Daniel L ^c   Bittman, Robert ^d   Tigyi, Gabor ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

^c University of Memphis   (United States)

^d CITY UNIVERSITY OF NEW YORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DICHLORO N (3 FLUOROPHENYL) 5 (4 MORPHOLINYLSULFONYL)BENZAMIDE; 4 OXO 4 [2 [(5 PHENOXY 1H INDOL 2 YL)CARBONYL]HYDRAZINO] N (4 PHENYLBUTAN 2 YL)BUTANAMIDE; ANTINEOPLASTIC AGENT; AUTOTAXIN; LYSOPHOSPHOLIPASE; N (2,6 DIMETHYLPHENYL) 2 [N (2 FURYLMETHYL)(4 (1,2,3,4 TETRAAZOLYL)PHENYL)CARBONYLAMINO] 2 (4 HYDROXY 3 METHOXYPHENYL)ACETAMIDE; PHOSPHODIESTERASE; PHOSPHOLIPASE INHIBITOR; UNCLASSIFIED DRUG;

ARTICLE; ENZYME SUBSTRATE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; IN VITRO STUDY; LUNG METASTASIS; MELANOMA CELL; PRIORITY JOURNAL; TUMOR INVASION;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; BENZENEACETAMIDES; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; HYDRAZINES; HYDROPHOBIC AND HYDROPHILIC INTERACTIONS; INDOLES; LUNG NEOPLASMS; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED C57BL; MOLECULAR DOCKING SIMULATION; MUTATION; NEOPLASM INVASIVENESS; PHOSPHODIESTERASE INHIBITORS; PHOSPHORIC DIESTER HYDROLASES; STRUCTURE-ACTIVITY RELATIONSHIP; SULFONAMIDES; TETRAZOLES;

EID: 84883138075     PISSN: 0026895X     EISSN: 15210111     Source Type: Journal    
DOI: 10.1124/mol.113.087080     Document Type: Article

References (48)

1. Albers HM, Dong A, van Meeteren LA, Egan DA, Sunkara M, van Tilburg EW, Schuurman K, van Tellingen O, Morris AJ, and Smyth SS, et al. (2010) Boronic acid-based inhibitor of autotaxin reveals rapid turnover of LPA in the circulation. Proc Natl Acad Sci USA 107: 7257-7262.
2. Albers HM and Ovaa H (2012) Chemical evolution of autotaxin inhibitors. Chem Rev 112: 2593-2603.
3. Baker DL, Fujiwara Y, Pigg KR, Tsukahara R, Kobayashi S, Murofushi H, Uchiyama A, Murakami-Murofushi K, Koh E, and Bandle RW, et al. (2006) Carba analogs of cyclic phosphatidic acid are selective inhibitors of autotaxin and cancer cell invasion and metastasis. J Biol Chem 281: 22786-22793.
4. Brindley DN, Lin FT, and Tigyi GJ (2013) Role of the autotaxin- lysophosphatidate axis in cancer resistance to chemotherapy and radiotherapy. Biochim Biophys Acta 1831: 74-85.
5. Chemical Computing Group Inc (2012) Molecular Operating Environment, MOE, Montreal.
6. Clair T, Aoki J, Koh E, Bandle RW, Nam SW, Ptaszynska MM, Mills GB, Schiffmann E, Liotta LA, and Stracke ML (2003) Autotaxin hydrolyzes sphingosylphosphorylcholine to produce the regulator of migration, sphingosine-1-phosphate. Cancer Res 63: 5446-5453.
7. David M, Wannecq E, Descotes F, Jansen S, Deux B, Ribeiro J, Serre CM, Grès S, Bendriss-Vermare N, and Bollen M, et al. (2010) Cancer cell expression of autotaxin controls bone metastasis formation in mouse through lysophosphatidic aciddependent activation of osteoclasts. PLoS ONE 5:e9741.
8. Duan RD, Bergman T, Xu N, Wu J, Cheng Y, Duan J, Nelander S, Palmberg C, and Nilsson A (2003) Identification of human intestinal alkaline sphingomyelinase as a novel ecto-enzyme related to the nucleotide phosphodiesterase family. J Biol Chem 278: 38528-38536.
9. Feng BY, Shelat A, Doman TN, Guy RK, and Shoichet BK (2005) High-throughput assays for promiscuous inhibitors. Nat Chem Biol 1: 146-148.
10. Ferry G, Moulharat N, Pradère JP, Desos P, Try A, Genton A, Giganti A, Beucher- Gaudin M, Lonchampt M, and Bertrand M, et al. (2008) S32826, a nanomolar inhibitor of autotaxin: discovery, synthesis and applications as a pharmacological tool. J Pharmacol Exp Ther 327: 809-819.
11. Gierse J, Thorarensen A, Beltey K, Bradshaw-Pierce E, Cortes-Burgos L, Hall T, Johnston A, Murphy M, Nemirovskiy O, and Ogawa S, et al. (2010) A novel autotaxin inhibitor reduces lysophosphatidic acid levels in plasma and the site of inflammation. J Pharmacol Exp Ther 334: 310-317.
12. Gijsbers R, Aoki J, Arai H, and Bollen M (2003) The hydrolysis of lysophospholipids and nucleotides by autotaxin (NPP2) involves a single catalytic site. FEBS Lett 538: 60-64.
13. Gotoh M, Fujiwara Y, Yue J, Liu J, Lee S, Fells J, Uchiyama A, Murakami-Murofushi K, Kennel S, and Wall J, et al. (2012) Controlling cancer through the autotaxinlysophosphatidic acid receptor axis. Biochem Soc Trans 40: 31-36.
14. Gupte R, Patil R, Liu J, Wang Y, Lee SC, Fujiwara Y, Fells J, Bolen AL, Emmons- Thompson K, and Yates CR, et al. (2011) Benzyl and naphthalene methylphosphonic acid inhibitors of autotaxin with anti-invasive and anti-metastatic activity. ChemMedChem 6: 922-935.
15. Gupte R, SiddamA, Lu Y, Li W, Fujiwara Y, Panupinthu N, PhamTC, Baker DL, Parrill AL, and Gotoh M, et al. (2010) Synthesis and pharmacological evaluation of the stereoisomers of 3-carba cyclic-phosphatidic acid. Bioorg Med Chem Lett 20: 7525-7528.
16. Hann MM and Oprea TI (2004) Pursuing the leadlikeness concept in pharmaceutical research. Curr Opin Chem Biol 8: 255-263.
17. Hausmann J, Kamtekar S, Christodoulou E, Day JE, Wu T, Fulkerson Z, Albers HM, van Meeteren LA, Houben AJ, and van Zeijl L, et al. (2011) Structural basis of substrate discrimination and integrin binding by autotaxin. Nat Struct Mol Biol 18: 198-204.
18. Hoeglund AB, Bostic HE, Howard AL, Wanjala IW, Best MD, Baker DL, and Parrill AL (2010) Optimization of a pipemidic acid autotaxin inhibitor. J Med Chem 53: 1056-1066.
19. Houben AJ and Moolenaar WH (2011) Autotaxin and LPA receptor signaling in cancer. Cancer Metastasis Rev 30: 557-565.
20. Ikeda H and Yatomi Y (2012) Autotaxin in liver fibrosis. Clin Chim Acta 413: 1817-1821.
21. Kawaguchi M, Okabe T, Okudaira S, Nishimasu H, Ishitani R, Kojima H, Nureki O, Aoki J, and Nagano T (2013) Screening and X-ray crystal structure-based optimization of autotaxin (ENPP2) inhibitors, using a newly developed fluorescence probe. ACS Chem Biol [published ahead of print].
22. Kehlen A, Englert N, Seifert A, Klonisch T, Dralle H, Langner J, and Hoang-Vu C (2004) Expression, regulation and function of autotaxin in thyroid carcinomas. Int J Cancer 109: 833-838.
23. Koh E, Clair T, Woodhouse EC, Schiffmann E, Liotta L, and Stracke M (2003) Sitedirected mutations in the tumor-associated cytokine, autotaxin, eliminate nucleotide phosphodiesterase, lysophospholipase D, and motogenic activities. Cancer Res 63: 2042-2045.
24. Kremer AE, van Dijk R, Leckie P, Schaap FG, Kuiper EM, Mettang T, Reiners KS, Raap U, van Buuren HR, and van Erpecum KJ, et al. (2012) Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology 56: 1391-1400.
25. Lipinski CA, Lombardo F, Dominy BW, and Feeney PJ (2001) Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev 46: 3-26.
26. Mills GB and Moolenaar WH (2003) The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 3: 582-591.
27. Mize CD, Abbott AM, Gacasan SB, Parrill AL, and Baker DL (2011) Ligand-based autotaxin pharmacophore models reflect structure-based docking results. J Mol Graph Model 31: 76-86.
28. Moolenaar WH, Houben AJ, Lee SJ, and van Meeteren LA (2013) Autotaxin in embryonic development. Biochim Biophys Acta 1831: 13-19.
29. Nikitopoulou I, Oikonomou N, Karouzakis E, Sevastou I, Nikolaidou-Katsaridou N, Zhao Z, Mersinias V, Armaka M, Xu Y, and Masu M, et al. (2012) Autotaxin expression from synovial fibroblasts is essential for the pathogenesis of modeled arthritis. J Exp Med 209: 925-933.
30. Nishimasu H, Ishitani R, Aoki J, and Nureki O (2012) A 3D view of autotaxin. Trends Pharmacol Sci 33: 138-145.
31. Nishimasu H, Okudaira S, Hama K, Mihara E, Dohmae N, Inoue A, Ishitani R, Takagi J, Aoki J, and Nureki O (2011) Crystal structure of autotaxin and insight into GPCR activation by lipid mediators. Nat Struct Mol Biol 18: 205-212.
32. North EJ, Howard AL, Wanjala IW, Pham TC, Baker DL, and Parrill AL (2010) Pharmacophore development and application toward the identification of novel, small-molecule autotaxin inhibitors. J Med Chem 53: 3095-3105.
33. Nouh MA, Wu XX, Okazoe H, Tsunemori H, Haba R, Abou-Zeid AM, Saleem MD, Inui M, Sugimoto M, and Aoki J et al. (2009) Expression of autotaxin and acylglycerol kinase in prostate cancer: association with cancer development and progression. Cancer Sci 100: 1631-1638.
34. Sakagami H, Aoki J, Natori Y, Nishikawa K, Kakehi Y, Natori Y, and Arai H (2005) Biochemical and molecular characterization of a novel choline-specific glycerophosphodiester phosphodiesterase belonging to the nucleotide pyrophosphatase/ phosphodiesterase family. J Biol Chem 280: 23084-23093.
35. Saunders LP, Ouellette A, Bandle R, Chang WC, Zhou H, Misra RN, De La Cruz EM, and Braddock DT (2008) Identification of small-molecule inhibitors of autotaxin that inhibit melanoma cell migration and invasion. Mol Cancer Ther 7: 3352-3362.
36. Schneider CA, Rasband WS, and Eliceiri KW (2012) NIH Image to ImageJ: 25 years of image analysis. Nat Methods 9: 671-675.
37. St-Coeur PD, Ferguson D, Morin P, Jr, and Touaibia M (2013) PF-8380 and closely related analogs: synthesis and structure-activity relationship towards autotaxin inhibition and glioma cell viability. Arch Pharm (Weinheim) 346: 91-97.
38. Stracke ML, Krutzsch HC, Unsworth EJ, Arestad A, Cioce V, Schiffmann E, and Liotta LA (1992) Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 267: 2524-2529.
39. Tager AM (2012) Autotaxin emerges as a therapeutic target for idiopathic pulmonary fibrosis: limiting fibrosis by limiting lysophosphatidic acid synthesis. Am J Respir Cell Mol Biol 47: 563-565.
40. Tigyi G (2010) Aiming drug discovery at lysophosphatidic acid targets. Br J Pharmacol 161: 241-270.
41. Trott O and Olson AJ (2010) AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem 31: 455-461.
42. Ueda H, Matsunaga H, Olaposi OI, and Nagai J (2013) Lysophosphatidic acid: chemical signature of neuropathic pain. Biochim Biophys Acta 1831: 61-73.
43. Veber DF, Johnson SR, Cheng H-Y, Smith BR, Ward KW, and Kopple KD (2002) Molecular properties that influence the oral bioavailability of drug candidates. J Med Chem 45: 2615-2623.
44. Wu J, Nilsson A, Jönsson BA, Stenstad H, Agace W, Cheng Y, and Duan RD (2006) Intestinal alkaline sphingomyelinase hydrolyses and inactivates plateletactivating factor by a phospholipase C activity. Biochem J 394: 299-308.
45. Wu JM, Xu Y, Skill NJ, Sheng H, Zhao Z, Yu M, Saxena R, and Maluccio MA (2010) Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer 9:71.
46. Yanagida K, Kurikawa Y, Shimizu T, and Ishii S (2013) Current progress in non-Edg family LPA receptor research. Biochim Biophys Acta 1831: 33-41.
47. Yang SY, Lee J, Park CG, Kim S, Hong S, Chung HC, Min SK, Han JW, Lee HW, and Lee HY (2002) Expression of autotaxin (NPP-2) is closely linked to invasiveness of breast cancer cells. Clin Exp Metastasis 19: 603-608.
48. Yang Y, Mou Lj, Liu N, and Tsao MS (1999) Autotaxin expression in non-small-cell lung cancer. Am J Respir Cell Mol Biol 21: 216-222.